Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Freyja-Maria Smolle-Juettner is active.

Publication


Featured researches published by Freyja-Maria Smolle-Juettner.


Radiotherapy and Oncology | 2001

Hyperbaric oxygen – an effective tool to treat radiation morbidity in prostate cancer

Ramona Mayer; Huberta Klemen; Franz Quehenberger; Oliver Sankin; Elisabeth Mayer; Arnulf Hackl; Freyja-Maria Smolle-Juettner

PURPOSE We report the results of hyperbaric oxygen therapy (HBO) used in the treatment of radiation cystitis and proctitis following irradiation of prostate cancer. MATERIALS AND METHODS Between June 1995 and March 2000, 18 men (median age 71 years) with radiation proctitis (n=7), cystitis (n=8), and combined proctitis/cystitis (n=3) underwent HBO therapy in a multiplace chamber for a median of 26 sessions (range 2-60). The treatment schedule (2.2-2.4 atmospheres absolute, 60 min bottom time, once-a-day, 7 days a week) was set at a lower limit of 20 sessions; the upper limit was left open to symptom-related adjustment. Prior to HBO treatment, RTOG/EORTC late genitourinal (GU) morbidity was Grade 2 (n=3), Grade 3 (n=6) or Grade 4 (n=2); modified RTOG/EORTC late gastrointestinal (GI) morbidity was either Grade 2 (n=4) or Grade 3 (n=6). RESULTS Sixteen patients underwent an adequate number of sessions. RTOG/EORTC late GU as well as modified GI morbidity scores showed a significant improvement after HBO (GI, P=0.004; GU, P=0.004; exact Wilcoxon signed rank test); bleeding ceased in five out of five patients with proctitis and in six out of eight patients with cystitis; one of those two patients, in whom an ineffective treatment outcome was obtained, went on to have a cystectomy. CONCLUSIONS HBO treatment seems to be an effective tool to treat those patients with late GI and GU morbidity when conventional treatment has led to unsatisfactory results. Particularly in patients with radiation cystitis, HBO should not be delayed too long, as in the case of extensive bladder shrinkage improvement is hard to achieve.


Resuscitation | 1997

A comparison of the end-tidal-CO2 documented by capnometry and the arterial pCO2 in emergency patients

G. Prause; H Hetz; Ph Lauda; H Pojer; Freyja-Maria Smolle-Juettner; Josef Smolle

Satisfactory artificial ventilation is defined as sufficient oxygenation and normo- or slight arterial hypocarbia. Monitoring end tidal CO2 values with non-invasive capnometry is a routine procedure in anaesthesia, emergency medicine and intensive care. In anaesthesia the ventilation volume is adjusted to the capnometric end tidal CO2 (ETCO2), taking into account a normal variation from the pACO2 of 3-8 mmHg. We evaluated the usefulness and practicability of using ETCO2 for correctly adjusting ventilation parameters in prehospital emergency care, by comparing arterial pCO2 and ETCO2 of 27 intubated and ventilated patients. We used the side-stream capnometry module of the Defigard 2000 (Bruker, ChemoMedica Austria) and a portable blood gas analyzer (OPTI 1, AVL Graz, Austria). Evaluation of the group of patients as a whole showed that there was no correlation whatsoever between the end expiratory and arterial CO2. Dividing the patients into three subgroups (1, During CPR; II, respiratory disturbances of pulmonary and cardiac origin; III, extrapulmonary respiratory disturbances), we found that only patients without primary cardiorespiratory damage showed a slight, but not statistically significant, correlation. This can be explained by the fact that almost any degree of cardiorespiratory failure causes changes of the ventilation-perfusion ratio, impairing pulmonary CO2 elimination. We conclude, that the ventilation of emergency patients can only be correctly adjusted according to values derived from an arterial blood gas analysis and ETCO2 measurements cannot be absolutely relied upon for accuracy except, perhaps, in patients without primary cardiorespiratory dysfunction.


Pathology Research and Practice | 1989

Vascular Architecture of Melanocytic Skin Tumors: A Quantitative Immunohistochemical Study Using Automated Image Analysis

Josef Smolle; Hp Soyer; R. Hofmann-Wellenhof; Freyja-Maria Smolle-Juettner; Helmut Kerl

The present study examines the distribution of blood vessels in melanocytic skin tumors. Fresh frozen sections of 11 cases each of benign nevocellular nevus, primary malignant melanoma and metastatic malignant melanoma were stained with the endothelium-specific monoclonal antibody BMA 120 and evaluated by an automated image analysis system. Additionally, the proliferative activity was assessed in parallel sections using Ki 67 monoclonal antibody. There were only slight differences between the diagnostic groups as to the vascular distribution in the tumor center, but there were remarkable differences in the connective tissue at the base of the lesions: The area occupied by small vessels (minimum diameter less than 20 microns) was 0.3 +/- 0.05% in benign nevi, 0.6 +/- 0.05% in primary malignant melanoma, and 1.2 +/- 0.10% in metastatic malignant melanoma (U-test: p less than or equal to 0.05). The proliferative activity within each lesion showed a strong positive correlation with the number of small vessels at the base of the tumor (linear regression analysis: r = 0.86; p less than or equal to 0.0001). The findings demonstrate that neovascularization in malignant melanocytic tumors takes place predominantly in the surrounding host tissue and is closely related to the proliferative activity.


Strahlentherapie Und Onkologie | 1999

Radiotherapy for invasive thymoma and thymic carcinoma. Clinicopathological review.

Ramona Mayer; Christine Beham-Schmid; Reinhard Groell; Freyja-Maria Smolle-Juettner; Franz Quehenberger; Georg Stuecklschweiger; Ulrike Prettenhofer; Heidi Stranzl; Heiko Renner; Arnulf Hackl

PurposeThis study reports clinicopathological features and outcome of thymic tumors. Twenty-seven patients with invasive thymoma and 6 patients with thymic carcinoma who had received radiotherapy either primary or postoperatively were analyzed retrospectively.Patients and MethodsAll 33 patients were irradiated with a mean dose of 50 Gy after complete resection (16 patients), partial resection (9 patients) or biopsy (8 patients). Staging was done according to the Masaoka classification; there were 12 Stage II, 12 Stage III and 9 Stage IV patients.ResultsIn patients with invasive thymoma Stage II to IV (median follow-up 54.4 months) Kaplan-Meier estimates of overall survival (OS), disease-specific (DSS) and disease-free survival (DFS) at 5 years were 63.7% (95% confidence interval [CI], 42 to 84%), 88.3% (CI, 75 to 100%) and 77.4% (CI, 58 to 95%), respectively. Among the prognostic factors tested, such as age, myasthenia gravis, completeness of surgery and histologic subclassification, total radiation dose, and Masaoka Stage, the latter was the only significant predictor of improved survival (p = 0.04). Considering local control, radiation dose was a significant prognostic factor (p = 0.0006). In patients with thymic carcinoma (median follow-up 43.4 months) 5-year DSS, and DFS were 22.2% (CI, 0 to 60%) and 16.7% (CI, 0 to 46%), respectively. Thymoma as compared to thymic carcinoma had a statistically significant better DSS (p = 0.007) and DFS (p = 0.0007).ConclusionPostoperative radiotherapy with sufficient doses plays an important role as adjuvant treatment in complete or incomplete resected invasive Stage II to III thymoma. In unresectable thymoma Stage III to IV as well as in thymic carcinoma a multimodality approach should be considered to improve survival.ZusammenfassungZielBericht über 27 Patienten mit invasivem Thymom und sechs Patienten mit Thymuskarzinom nach primärer oder postoperativer Strahlentherapie unter besonderer Berücksichtigung der pathohistologischen Befunde und klinischen Ergebnisse.Patienten und MethodenAlle 33 Patienten wurden nach kompletter Resektion (n = 16), Teilresektion (n = 9) oder Biopsie (n = 8) mit einer mittleren Dosis von 50 Gy (30 bis 60 Gy) bestrahlt. Die Stadieneinteilung nach Masaoka (Tabelle 1) ergab jeweils zwolf Patienten in Stadium II und III sowie neun Patienten im Stadium IV (Tabelle 2).ErgebnissePatienten mit einem invasivem Thymom Masaoka-Stadium II bis IV (mediane Nachsorgezeit 54,4 Monate) hatten ein Fünf-Jahres-Gesamüberleben, krankheitsspezifisches und krankheitsfreies Überleben von 63,7% (95%Konfidenzintervall [KI] 42 bis 84%), 88,3% (KI 75 bis 100%) sowie 77,4% (KI 58 bis 95%). Bei den untersuchten prognostischen Faktoren, wie Alter, Myasthenia gravis, chirurgische Radikalität, histologische Subgruppe, Bestrahlungsdosis und Masaoka-Stadium, hatte nur letzteres einen stätistisch signifikanten Einfluß auf das Überleben (p = 0.04). (Tabelle 8). Bei alleiniger Berücksichtigung der lokalen Kontrolle war die Bestrahlungsdosis ein stätistisch signifikanter prognostischer Parameter (p = 0,0006) (Tabelle 7). Patienten mit Thymuskarzinom (mediane Nachsorgezeit 43,3 Monate) hatten ein krankheitsspezifisches und krankheitsfreies Fünf-Jahres-Überleben von 22,2% (KI 0 bis 60%) sowie 16,7% (KI 0 bis 46%). Patienten mit Thymomen hatten im Vergleich zu Patienten mit Thymuskarzinomen sowohl ein statistisch signifikant besseres krankheitsspezifisches (p = 0,007) als auch krankheitsfreies Überleben (p = 0,0007) (Abbildung 1).SchlußfolgerungPostoperative Strahlentherapie mit adäquater Dosis spielt eine wichtige Rolle als adjuvante Therapie bei inkomplett und komplett resezierten invasiven Thymomen Stadium II bis III. Bei primär inoperablen Thymomen und bei Thymuskarzinom sollte ein multimodales Vorgehen in Erwägung gezogen werden, urn die Überlebensraten zu verbessern.


European Journal of Cardio-Thoracic Surgery | 1998

Is aggressive surgery in pleural empyema justified

Heiko Renner; Sabine Elisabeth Gabor; Hans Pinter; Alfred Maier; Gerhard B. Friehs; Freyja-Maria Smolle-Juettner

OBJECTIVE High risk and a long hospitalization time are often quoted as negative aspects of aggressive surgery in pleural empyema. We did a retrospective analysis evaluating outcome and duration of hospitalization in patients treated according to an aggressive schedule. METHODS Since 1989 we have treated 101 patients with pleural empyema (72 males, 29 females; mean age 50.3 years, range 11-91 years; 77 metapneumonic empyema, 24 empyema following trauma or abdominal surgery). Sixty-nine patients had had unsuccessful conservative pre-treatment (antibiotics, thorcozentses, drainage/irrigation, VATS). Thirty-one were critically ill patients. In eight cases a seropurulent stage of empyema was present, 17 patients had fibrinous membranes, 30 an organizing stage with and 46 without well identifiable dissection plane. Eighty-five patients proceeded to thoracotomy. Pulmonary abscesses or indurative pneumonia necessitated wedge-resection, lobectomy, or pneumonectomy in 29 cases. In the presence of gross necroses or callosities not amenable to decortication primary open-window thoracostomy (n = 22) was carried out. In six cases a secondary open-window thoracostomy was carried out because of persisting putrid secretion and sepsis persisting after decortication or after drainage. The thoracostomy was closed when clean granulative tissue developed. Sixteen patients underwent only drainage and irrigation because of an early stage or because of a general condition not permitting thoracotomy. RESULTS Three patients died due to severe sepsis not responding to treatment, one had fatal bleeding from a duodenal ulcer (mortality rate 3.9%). The others were able to resume their preoperative activities. The median duration of hospitalization was 14 days (mean 21.1 days; SEM 1.7 days). CONCLUSION Aggressive surgery for pleural empyema beyond the seropurulent stage ensures rapid relief from sepsis at a low mortality rate even in very ill patients.


European Journal of Cardio-Thoracic Surgery | 1996

“Adjuvant” external radiation of the mediastinum in radically resected non-small cell lung cancer

Freyja-Maria Smolle-Juettner; R. Mayer; Hans Pinter; G. Stuecklschweiger; K. S. Kapp; S. Gabor; B. Ratzenhofer; Arnulf Hackl; Gerhard Friehs; C. Gebitekin; M. Ribet; P. Bruecke

OBJECTIVE The effect of postoperative external beam radiation in MO non-small cell lung cancer resected with curative intention was evaluated in a randomized trial. METHODS In 155 patients (121 males, 34 females; mean age: 59 years) 105 lobectomies, 12 bilobectomies and 38 pneumonectomies with radical lymph node dissection to the contralateral side were carried out. Histology revealed squamous cell (n = 68), adeno- (n = 53), large cell (n = 21), adenosquamous (n = 6) or bronchioloalveolar type (n = 7) carcinomas. The pathologic stages T1 (n = 38), T2 (n = 89), T3 (n = 28); NO (n = 39), N1 (n = 67), and N2 (n = 49) were evenly distributed between the two treatment groups: group A (72 patients) had no further oncologic treatment, while group B (83 patients) had external beam radiation to the mediastinum (50-56 Gy, 8 or 23 MeV photons, 2 Gy/day, 5 days a week) beginning 4 weeks after the operation. RESULTS The overall 5-year survival rate of the whole collective was 24.1% without any significant difference between the radiotherapy group B (29.7%) and the control group A (20.4%) (log-rank test: P > 0.05). The overall 5-year recurrence-free survival rate was 20.1%, with no difference between groups B and A (radiotherapy: 22.7, controls: 15.6%, long-rank test: P > 0.05). There was no difference in the incidence of distant metastases (external beam radiation: n = 32; controls: n = 38). The rate of local recurrences at the bronchial stump or in the mediastinum, however, was significantly reduced in the radiotherapy group (n = 5) compared with 17 in the controls (P < 0.01 chi-square test). A multivariate analysis confirmed the independent influence of postoperative radiotherapy on the incidence of local recurrence. CONCLUSIONS External radiation of the mediastinum in radically resected non-small cell lung cancer reduces the risk of local recurrence, but has no influence on distant metastastic spread and overall survival.


Frontiers of Radiation Therapy and Oncology | 2010

Resection in Stage I/II Non-Small Cell Lung Cancer

Freyja-Maria Smolle-Juettner; Alfred Maier; Joerg Lindenmann; Veronika Matzi; N. Neuböck

In spite of the developments in chemo- and radiotherapy, surgery remains the mainstay of curative treatment of early stage non-small cell lung cancer (NSCLC). In stage Ia/Ib (T1, T2, N0), NSCLC lobectomy offers the best chance for cure, yielding survival rates of between 58 and 76%. Since the extent of mediastinal lymph node dissection does not seem to play a major prognostic role in stage Ia, video-thoracoscopic lobectomy yields equally good results as the open approach. Due to the necessity for a small thoracotomy when harvesting the specimen and the time-consuming lymph-node dissection minimally invasive lobar resections have failed to become routinely used. Minor resections, though sometimes necessary from the functional point of view, have a lower curative potential. They yield the best results if applied in tumors measuring less than 2 cm. Stage II, characterized by involvement of the N1-position and/or a more central tumor growth, has a 5-year survival of 45-52% and requires treatment by lobectomy or pneumonectomy. Sleeve resection may obviate the need for pneumonectomy in central upper-lobe tumors. In interlobar N1, however, pneumonectomy is indicated from the oncological point of view, since even meticulous lymph-node dissection is unable to achieve tumor control in this situation.


Acta Anaesthesiologica Scandinavica | 1998

Operations on patients deemed "unfit for operation and anaesthesia": what are the consequences?

G. Prause; Beatrice Ratzenhofer-Komenda; Freyja-Maria Smolle-Juettner; H. Krenn; H Pojer; W. Toller; H. Voit; A. Offner; Josef Smolle

Background: The decision “patient unfit for anaesthesia and operation” is likely to cause a delay of the scheduled operation. This retrospective evaluation was done: 1) to determine the correctness of preoperative tentative diagnoses of coexisting diseases making anaesthesia and operation excessively risky in relation to the physicians training status; 2) to examine the question of whether preoperative medical management modified according to the anaesthesiologists suggestions had a positive impact on the perioperative course.


European Journal of Cardio-Thoracic Surgery | 1997

Life-saving muscle flaps in tracheobronchial dehiscence following resection or trauma

Freyja-Maria Smolle-Juettner; Pierer G; Schwarzl F; Hans Pinter; Ratzenhofer B; G. Prause; Gerhard Friehs

OBJECTIVE In the presence of acute inflammation and necrosis of the wall, tracheo-bronchial defects are difficult to manage. The absence of adequate vascularization and the contaminated area prevent successful direct re-suturing. METHODS In order to restore a sufficient blood supply we used a pedicled latissimus dorsi or a pectoralis major flap that was entered into the thorax after a 10-cm resection of the second rib. A portion of the muscle was fitted into the tracheo/bronchial defect by reinforced sutures. The remaining muscle was sutured to the tissue surrounding the defect. This method was applied in various septic conditions: Bronchial defects; complete dehiscence of the right (n = 6) or left (n = 1) main bronchus at the carinal level following resection for lung cancer (n = 4) or for tuberculous (n = 2) on nontuberculous pleuropneumonia (n = 1). Tracheal defects; (1) destruction of one third of the tracheal circumference involving the cricoid down to the fourth ring following tracheotomy in presence of a septic sternum after intrathoracic goiter and Bechterews disease; (2) 30% dehiscence of the anastomosis and septic sternum following tracheal resection; (3) Mediastinitis involving tracheal and esophageal wall following a 7 cm long iatrogenous laceration of the intrathoracic trachea. RESULTS In one case the latissimus dorsi developed venous stasis on day 2 and was replaced by the pectoralis major muscle which showed uneventful healing. In all other patients the muscle flap resulted in an uneventful closure of the defect and recovery. CONCLUSIONS Large, well vascularized, pedicled muscle flaps ensure a safe closure of tracheo-bronchial defects or dehiscences even in presence of gross necrosis and sepsis.


Inhalation Toxicology | 2006

Hyperbaric oxygenation in the treatment of life-threatening isobutyl nitrite-induced methemoglobinemia--a case report.

Joerg Lindenmann; Veronika Matzi; P. Kaufmann; P. Krisper; Alfred Maier; Christian Porubsky; Freyja-Maria Smolle-Juettner

Methemoglobinemia usually results from exposure to oxidizing substances such as nitrates or nitrites. Iron within hemoglobin is oxidized from the ferrous (Fe2+) state to the ferric (Fe3+) state, resulting in the inability to transport oxygen and carbon dioxide. Clinically, this condition causes functional cyanosis. As methemoglobin levels increase, patients show evidence of cellular hypoxia in all tissues. Death usually occurs when methemoglobin fractions approach 70% of total hemoglobin. We describe the case of a 35-year-old female patient with severe life-threatening isobutyl nitrite-induced methemoglobinemia of 75% of total hemoglobin. Toluidine-blue was administered as first-line antidotal therapy immediately, followed by hyperbaric oxygenation. The patient recovered uneventfully and could be discharged 3 days later.

Collaboration


Dive into the Freyja-Maria Smolle-Juettner's collaboration.

Top Co-Authors

Avatar

Josef Smolle

Medical University of Graz

View shared research outputs
Top Co-Authors

Avatar

Alfred Maier

Medical University of Graz

View shared research outputs
Top Co-Authors

Avatar

Joerg Lindenmann

Medical University of Graz

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Veronika Matzi

Medical University of Graz

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Nicole Neuboeck

Medical University of Graz

View shared research outputs
Researchain Logo
Decentralizing Knowledge